FreeOx Biotech is an innovative company born to discover and develop medicines addressed to reduce the effects of the oxidative stress in the organism, and especially those related to the neurological and cardiovascular system.
We are focused mainly in Stroke, a condition characterised by the interruption of blood flow to the brain which is a leading cause of death and disability worldwide.
FreeOx’s lead product is Ox-01; a molecule with neuroprotective properties that has a proven effect in preventing the damage caused by reperfusion after stroke. Ox-01 has finished phase IIb clinical trial demonstrated that it would be particularly useful in patients undergoing mechanical thrombectomy.
FreeOx Biotech was founded in March 2017 by five co-founders coming from Barcelona and Pittsburgh: Carlos Lurigados, Ángel Chamorro, Ángel Honrado, Tudor G. Jovin, and Juan Bigorra.
We are focused mainly in Stroke, a condition characterised by the interruption of blood flow to the brain which is a leading cause of death and disability worldwide.
FreeOx’s lead product is Ox-01; a molecule with neuroprotective properties that has a proven effect in preventing the damage caused by reperfusion after stroke. Ox-01 has finished phase IIb clinical trial demonstrated that it would be particularly useful in patients undergoing mechanical thrombectomy.
FreeOx Biotech was founded in March 2017 by five co-founders coming from Barcelona and Pittsburgh: Carlos Lurigados, Ángel Chamorro, Ángel Honrado, Tudor G. Jovin, and Juan Bigorra.
Location: Spain, Catalonia, Barcelona
Employees: 1-10
Total raised: $3.02M
Founded date: 2017
Funding Rounds 3
| Date | Series | Amount | Investors |
| 06.12.2023 | Seed | $1.84M | - |
| 16.11.2018 | - | $571.03K | - |
| 06.04.2018 | - | $614.39K | - |
Mentions in press and media 4
| Date | Title | Description |
| 06.12.2023 | FreeOx Biotech Raises €1.7M Seed Funding | FreeOx Biotech, a Barcelona, Spain-based late-stage clinical biopharmaceutical company, raised €1.7M in the first close of its seed funding. Backers included investors in Canada, the U.S., Spain, and Israel. The company also announced the f... |
| 09.11.2018 | FreeOx Biotech cierra su 1ª ronda de €500.000, acuden Montserrat Esteve y Francisco Javier Alsina | 09/11/2018 Nota de prensa FREEOX BIOTECH CIERRA SU PRIMERA RONDA DE €500.000, ACUDEN LOS BUSINESS ANGELS MONTSERRAT ESTEVE Y FRANCISCO JAVIER ALSINA. FreeOx Biotech, spin-out del Hospital Clínic de Barcelona-IDIBAPS creada en 2017 que de... |
| 08.11.2018 | FreeOx Closes €500K in Funding | FreeOx Biotech, a Barcelona, Spain-based developer of a new class of neuroprotective drugs, closed its €500k first round of funding. Backers included Montserrat Esteve and Francisco Javier Alsina. Created in 2017 as a spin-out of Hospital C... |
| - | FreeOx Biotech | “FreeOx |” |